Get the Stockscreener App
16.27
0.06%
-0.01
After Hours:
16.58
0.31
+1.91%
Myriad Genetics Inc stock is traded at $16.27, with a volume of 338.68K.
It is down -0.06% in the last 24 hours and down -26.94% over the past month.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
See More
Previous Close:
$16.28
Open:
$16.29
24h Volume:
338.68K
Relative Volume:
0.43
Market Cap:
$1.48B
Revenue:
$802.20M
Net Income/Loss:
$-155.20M
P/E Ratio:
-4.8423
EPS:
-3.36
Net Cash Flow:
$-141.30M
1W Performance:
+5.04%
1M Performance:
-26.94%
6M Performance:
-28.33%
1Y Performance:
-15.44%
1-Day Range:
$16.11
$16.52
1-Week Range:
$15.56
$16.53
52-Week Range:
$14.72
$29.30
Myriad Genetics Inc Stock (MYGN) Company Profile
Name
Myriad Genetics Inc
Sector
Industry
Phone
801-584-3600
Address
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
16.27 | 1.48B | 802.20M | -155.20M | -141.30M | -1.81 |
|
TMO
Thermo Fisher Scientific Inc
|
529.63 | 202.58B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
239.69 | 173.12B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
137.97 | 39.35B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
200.84 | 36.45B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
421.75 | 34.53B | 3.84B | 866.24M | 792.60M | 10.37 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-19-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Underperform |
| May-08-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-21-23 | Resumed | Piper Sandler | Neutral |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Underweight |
| May-23-23 | Upgrade | Goldman | Sell → Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-06-22 | Initiated | Stephens | Equal-Weight |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Sell |
| Sep-26-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Aug-14-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-02-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Aug-01-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Downgrade | Needham | Strong Buy → Hold |
| Jul-09-19 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-12-19 | Reiterated | Needham | Strong Buy |
| Jan-03-19 | Initiated | Needham | Strong Buy |
| Nov-30-18 | Upgrade | Goldman | Sell → Neutral |
| Oct-10-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-11-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-21-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-29-18 | Initiated | Goldman | Sell |
| Jan-22-18 | Reiterated | Barclays | Equal Weight |
| Jan-05-18 | Initiated | BTIG Research | Buy |
| Oct-02-17 | Resumed | Leerink Partners | Mkt Perform |
| Aug-09-17 | Reiterated | Barclays | Equal Weight |
| Feb-08-17 | Upgrade | Ladenburg Thalmann | Sell → Neutral |
| Jan-18-17 | Initiated | Deutsche Bank | Sell |
| Oct-10-16 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
View All
Myriad Genetics Inc Stock (MYGN) Latest News
MYGN Beats on Q3 Earnings and Revenues, Raises '24 EPS View - MSN
Fisher Asset Management LLC Boosts Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Why Myriad Genetics, Inc. Shares Soared - AOL
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives $27.36 Average PT from Analysts - MarketBeat
Myriad Genetics settles shareholder lawsuits, agrees to reforms - Investing.com India
Myriad Genetics settles shareholder lawsuits, agrees to reforms By Investing.com - Investing.com UK
Myriad Genetics Reforms Corporate Governance to Settle Lawsuits - Bloomberg Law
Myriad Genetics, Inc. (NASDAQ:MYGN) Stock Position Lifted by Loomis Sayles & Co. L P - MarketBeat
MYGN Stock Up on Integration of HRD Platform Into Illumina's TSO 500 v2 - MSN
This Week in Chancery Court: Myriad Genetics Settlement Ruling - Bloomberg Law
Connor Clark & Lunn Investment Management Ltd. Boosts Stock Position in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
(MYGN) Trading Report - Stock Traders Daily
Natixis Advisors LLC Buys 44,646 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Gene Panel Market to Surpass USD 11.75 Billion by 2031 | SkyQuest Technology - GlobeNewswire Inc.
Clinical Oncology Next Generation Sequencing (NGS) Market - openPR
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2 - The Manila Times
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2 - GlobeNewswire
Myriad Genetics Expands Illumina Partnership, Integrates Key Cancer Testing Technology | MYGN Stock News - StockTitan
MYGN Stock Might Gain From SneakPeek Availability in Retail Stores - MSN
Myriad Genetics (NASDAQ:MYGN) Downgraded to "Hold" Rating by StockNews.com - MarketBeat
Breast Cancer Screening and Diagnostic Techniques Market - openPR
Myriad Genetics (NASDAQ:MYGN) Reaches New 12-Month Low Following Analyst Downgrade - MarketBeat
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy - GlobeNewswire
Myriad Genetics Launches Industry's First 8-Week Prenatal DNA Screen | MYGN Stock News - StockTitan
Myriad Genetics price target lowered to $21 from $32 at Morgan Stanley - Yahoo Finance
Myriad Genetics (NASDAQ:MYGN) Given New $21.00 Price Target at Morgan Stanley - MarketBeat
State of New Jersey Common Pension Fund D Acquires New Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC - GlobeNewswire
Simplify Asset Management Inc. Buys Shares of 173,626 Myriad Genetics, Inc. (NASDAQ:MYGN) - MarketBeat
Predictive Genetic Testing & Consumer/Wellness Genomics Market Projected to Reach USD 17.66 Billion by 2032, Growing at a 13.33% CAGR – SNS Insider - GlobeNewswire
Predictive Genetic Testing & Consumer/Wellness Genomics - GlobeNewswire
Long Term Trading Analysis for (MYGN) - Stock Traders Daily
Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch - The Manila Times
Minimal Residual Disease Testing Market Share, Growth Drivers, - openPR
Myriad Genetics, Inc. (NASDAQ:MYGN) Just Reported Earnings, And Analysts Cut Their Target Price - Simply Wall St
Myriad Genetics stock hits 52-week low at $16.6 amid market shifts - Investing.com Australia
Myriad Genetics Inc (MYGN) Shares Gap Down to $16.76 on Nov 12 - GuruFocus.com
Myriad Genetics: Healthcare Marketing Impact Awards 2024 - Modern Healthcare
How Myriad Genetics helped address the gap in genetic testing among women - Ad Age
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Myriad Genetics, Inc. (MYGN) and Encourages Investors to Learn More About the Investigation - AccessWire
Myriad Genetics, Inc. (NASDAQ:MYGN) Q3 2024 Earnings Call Transcript - Insider Monkey
Piper Sandler Has Lowered Expectations for Myriad Genetics (NASDAQ:MYGN) Stock Price - MarketBeat
U.S. Women Health Laboratory Testing Market to Witness - openPR
Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Myriad Genetics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Myriad Genetics Inc (MYGN) Quarterly 10-Q Report - Quartzy
Myriad Genetics Inc (MYGN) Q3 2024 Earnings Call Highlights: Str - GuruFocus.com
Myriad Genetics Inc (MYGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Policy ... - Yahoo Finance
Myriad Genetics earnings beat by $0.04, revenue topped estimates - Investing.com Canada
Myriad: Q3 Earnings Snapshot - Marketscreener.com
Myriad Genetics Inc Stock (MYGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):